Fasting Insulin as an Independent Predictor of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Severity

被引：0
作者：
Harrison, Stephen A.
Dubourg, Julie
Jeannin, Sophie
Colca, Jerry R.
Ratziu, Vlad
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1582-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1582-P
引用
收藏
页数：3
相关论文
共 50 条
  • [31] MACHINE LEARNING MODELS FOR PREDICTING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE GENERAL UNITED STATES POPULATION
    Khalid, J.
    Aparasu, R. R.
    VALUE IN HEALTH, 2024, 27 (06) : S268 - S268
  • [32] Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study
    Kumar, Jata Shankar
    Bhardwaz, Priyanshu
    Kar, Premashis
    JOURNAL OF HEPATOLOGY, 2024, 80 : S609 - S610
  • [33] THERAPEUTIC HORIZONS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE( MASLD) & METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS( MASH): A SYSTEMATIC REVIEW OF CURRENT TREATMENT OPTION
    Moliya, Pratiksha
    Al-Obaidi, Hasan
    Patel, Pranav
    Patel, Raj
    Parikh, Charmy
    Joy, Melvin
    HEPATOLOGY, 2024, 80
  • [34] Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
    Younossi, Zobair M.
    Razavi, Homie
    Sherman, Michael
    Allen, Alina M.
    Anstee, Quentin M.
    Cusi, Kenneth
    Friedman, Scott L.
    Lawitz, Eric
    Lazarus, Jeffrey V.
    Schuppan, Detlef
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Vos, Miriam B.
    Wong, Vincent Wai-Sun
    Ratziu, Vlad
    Hompesch, Marcus
    Sanyal, Arun J.
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, : 1467 - 1478
  • [35] New and emerging treatments for metabolic dysfunction-associated steatohepatitis
    Tincopa, Monica A.
    Anstee, Quentin M.
    Loomba, Rohit
    CELL METABOLISM, 2024, 36 (05) : 912 - 926
  • [36] The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis
    Charlton, Michael
    Tonnu-Mihara, Ivy
    Teng, Chia-Chen
    Zhou, Ziqi
    Asefaha, Feven
    Luthra, Rakesh
    Hoovler, Anthony
    Uzoigwe, Chioma
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 919 - 930
  • [37] Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis
    Kanwal, Fasiha
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04) : 371 - 372
  • [38] Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis
    Qin, Xueying
    Liu, Jingjing
    ACTA BIOMATERIALIA, 2024, 184 : 37 - 53
  • [39] Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
    Devasia, Arun George
    Ramasamy, Adaikalavan
    Leo, Chen Huei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)
  • [40] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
    Loomba, Rohit
    Hartman, Mark L.
    Lawitz, Eric J.
    Vuppalanchi, Raj
    Boursier, Jerome
    Bugianesi, Elisabetta
    Yoneda, Masato
    Behling, Cynthia
    Cummings, Oscar W.
    Tang, Yuanyuan
    Brouwers, Bram
    Robins, Deborah A.
    Nikooie, Amir
    Bunck, Mathijs C.
    Haupt, Axel
    Sanyal, Arun J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04) : 299 - 310
12345